India RNA-Based Therapeutics Market Overview
As per MRFR analysis, the India RNA-Based Therapeutics Market Size was estimated at 385 (USD Million) in 2023. The India RNA-Based Therapeutics Market Industry is expected to grow from 524(USD Million) in 2024 to 1,854 (USD Million) by 2035.The India RNA-Based Therapeutics Market CAGR (growth rate) is expected to be around 12.173% during the forecast period (2025 - 2035).
Key India RNA-Based Therapeutics Market Trends Highlighted
The India RNA-Based Therapeutics Market is experiencing significant growth driven by various key market drivers, including the increasing prevalence of genetic disorders and infectious diseases. The rise in healthcare spending by both public and private sectors enhances the capacity for RNA-based research and development. Government initiatives, such as the Biotechnology Industry Research Assistance Council (BIRAC), promote innovation in biotechnology, underscoring India's commitment to advancing RNA therapies.
Moreover, collaborations between academic institutions and biopharmaceutical companies are gaining momentum, leading to enhanced R&D capabilities in RNA therapeutics. Opportunities to be explored in the RNA-based therapeutics space include the burgeoning interest in personalized medicine and the development of advanced vaccine technologies. India’s rich biodiversity also offers a unique opportunity for discovery and development of novel RNA-based treatments.
Furthermore, the ongoing focus on improving healthcare infrastructure, particularly post-pandemic, opens avenues for greater adoption of RNA therapies in disease management and prevention. Trends in recent times emphasize the rising adoption of messenger RNA (mRNA) technology, particularly in vaccine development, spotlighting India's role in global health initiatives.
Collaborations with global pharmaceutical companies and local startups are fostering a vibrant ecosystem for RNA therapeutics innovation. The government’s support for biotechnology start-ups and emphasis on clinical trials is further accelerating the progress in RNA therapeutic solutions. As regulatory pathways become more streamlined, India is poised to play a significant role in the global RNA therapeutics landscape, making it an attractive hub for investment and innovation in this field.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
India RNA-Based Therapeutics Market Drivers
Increasing Prevalence of Genetic Disorders
The incidence of genetic disorders has been on the rise in India, attributed to both lifestyle changes and environmental factors. According to the Indian Council of Medical Research, approximately 6-8% of the population is affected by genetic disorders, indicating a significant treatment gap. This growing number of patients suffering from conditions such as cystic fibrosis and muscular dystrophy drives the demand for RNA-based therapeutics.
Organizations like the All India Institute of Medical Sciences are actively engaged in Research and Development, working on novel RNA therapies to combat these disorders. The increasing awareness among healthcare providers and patients about genetic disorders enhances the growth prospects of the India RNA-Based Therapeutics Market Industry.
Government Initiatives and Funding
The Indian Government has intensified its focus on bio-pharmaceutical advancements through initiatives like the 'Make in India' campaign, aimed at boosting domestic manufacturing of bio-pharmaceutical products, including therapeutics based on RNA technology. The Department of Biotechnology has increased the budget allocation for biotechnology research, which is projected to provide significant funding opportunities for innovative RNA-based projects.
Such investment indicates strong support that might at least double the yearly growth rate of the India RNA-Based Therapeutics Market Industry. Furthermore underlining the sector's expansion, partnerships with reputable companies like the Biotechnology Industry Research Assistance Council inspire the creation of RNA treatments.
Advancements in Delivery Mechanisms
The discovery of advanced and efficient delivery mechanisms for RNA therapeutics has played a critical role in market expansion. Innovations, such as lipid nanoparticles and viral vectors, have notably improved the delivery of RNA therapies into target cells. Research institutions like the Indian Institute of Technology are conducting pioneering studies on these mechanisms, contributing to the increase in efficacy and patient compliance.
The positive outcomes from these studies indicate that improved delivery systems are key facilitators for the uptake of RNA-based therapeutics, hence propelling the India RNA-Based Therapeutics Market Industry.
India RNA-Based Therapeutics Market Segment Insights
RNA-Based Therapeutics Market Technology Insights
The India RNA-Based Therapeutics Market, particularly within the Technology segment, is witnessing significant advancements and innovations that are shaping the future of healthcare in the region. This segment encompasses various critical technologies, including RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology, each playing a vital role in the development of novel therapeutic approaches.
RNA Interference has emerged as a powerful mechanism for gene silencing, which enables the targeted treatment of diseases by modulating gene expression. This method is particularly effective in conditions such as cancer and genetic disorders, making it a focus area for research and development in India. Antisense Oligonucleotides represent another essential aspect of this market, as they allow for the specific alteration of mRNA function, thereby enabling the treatment of a variety of illnesses including rare genetic diseases, showcasing their significant therapeutic potential within the Indian healthcare landscape.
mRNA Therapeutics have gained substantial attention, especially in light of recent global health challenges, demonstrating efficacy in vaccines and potential applications across numerous therapeutic areas. This technology is pivotal for the Indian market, highlighting the importance of swift and adaptable therapeutic development in response to emerging infectious diseases. Additionally, CRISPR Technology is revolutionizing the way genetic diseases are treated, providing unparalleled precision in gene editing.
Its potential applications in agricultural biotechnology and medicine offer exciting prospects for India, which is focusing on enhancing healthcare and agricultural outcomes through innovative technologies. The synergy among these technologies not only sparks advancements in health solutions but also contributes to India’s position as a growing hub for biotechnology research and innovation. As the landscape continues to evolve, these technologies are set to dominate the India RNA-Based Therapeutics Market, driven by investment in research, increasing demand for advanced therapies, and supportive government initiatives aimed at fostering growth within the biotechnology sector, ultimately aiming to improve patient outcomes and public health across the nation.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
RNA-Based Therapeutics Market Application Insights
The Application segment of the India RNA-Based Therapeutics Market plays a critical role in addressing various health challenges by focusing on several key areas, including Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. This segment is characterized by the growing interest in RNA-based therapies as effective treatments for cancer, which has seen a surge in research and development due to rising cancer incidences in the country.
Infectious Diseases have also gained attention, particularly in light of recent global health crises, leading to an accelerated push towards RNA vaccines and therapeutics that can be rapidly developed and deployed. Genetic Disorders represent another significant area, with advancements in gene editing technologies highlighting the potential for RNA-based treatments to offer solutions for hereditary conditions. Additionally, Cardiovascular Diseases remain a leading cause of mortality in India.
The focus on developing RNA therapeutics in this segment offers promising avenues for innovative treatment options. As the healthcare system continues to evolve, the demand for advanced treatment modalities across these applications is expected to grow, driven by increasing public awareness, government initiatives, and ongoing technological advancements in RNA research and production.
RNA-Based Therapeutics Market End Use Insights
The India RNA-Based Therapeutics Market showcases significant engagement from various end users, prominently including Pharmaceutical Companies, Research Institutions, and Contract Research Organizations. Pharmaceutical Companies play a crucial role, focusing on the development and commercialization of RNA-based drugs, indicated for their potential in treating complex diseases such as cancer and genetic disorders, thus significantly driving innovation in therapeutics.
Research Institutions contribute tremendously by advancing foundational studies and clinical trials that underscore the therapeutic applications of RNA technologies, positioning India as a hub for cutting-edge research. Meanwhile, Contract Research Organizations offer essential support by providing specialized services in drug development processes, ensuring that pharmaceutical companies can leverage external expertise and resources to expedite market entry.
Collectively, these segments are aimed at tapping into the growing demand for RNA-based therapies in India, fueled by increasing investments in biotechnology and a strong regulatory push from the Indian government to foster health innovation. The synergy among these end users not only enhances product development timelines but also contributes to improving patient outcomes, thus laying a solid foundation for market expansion in the years to come.
RNA-Based Therapeutics Market Delivery Method Insights
The Delivery Method segment of the India RNA-Based Therapeutics Market is essential for the effective translation of RNA-based therapies from research into clinical applications. Various methods, such as Liposomes, Nanoparticles, Viral Vectors, and Electroporation, play crucial roles in determining the efficacy and safety of RNA therapeutics.
Liposomes are significant as they enhance cellular uptake and provide a protective encapsulation for RNA molecules. Nanoparticles facilitate improved targeting and controlled release of therapeutics, promoting precise delivery to target cells. Viral Vectors serve as powerful tools for gene delivery, allowing high efficiency in transferring RNA to the desired cells, which is particularly important for gene therapies. Electroporation is also notable; it employs electrical fields to increase cell permeability, thereby also facilitating the introduction of RNA into cells effectively.
The increasing investments in Research and Development, coupled with a supportive regulatory environment in India, further bolster the growth of innovative delivery methods within the market, driving advancements and expanding treatment options in the RNA therapeutics landscape.
India RNA-Based Therapeutics Market Key Players and Competitive Insights
The India RNA-Based Therapeutics Market has witnessed significant growth in recent years, driven by advancements in biotechnology and increasing investments in research and development. The competitive insights of this market reveal a landscape characterized by innovation, technology-driven approaches, and a focus on addressing unmet medical needs. Key players in the field are actively engaged in developing novel RNA-based therapies, which have emerged as promising options for various diseases, including genetic disorders, cancers, and viral infections.
The market is evolving rapidly due to collaborations between pharmaceutical companies and research institutions, alongside a rise in awareness about the potential of RNA-based treatments. These dynamics have prompted companies to strategically position themselves to capitalize on market opportunities by enhancing their product portfolios and exploring new therapeutic areas.
Wockhardt has established a notable presence in the India RNA-Based Therapeutics Market, leveraging its extensive expertise in bio-pharmaceuticals and a robust research infrastructure. The company's strengths lie in its commitment to quality and innovation, which have enabled it to develop a range of RNA-based products that cater to emerging therapeutic needs. With a focus on advancing biotechnology capabilities, Wockhardt is actively involved in developing solutions that address significant health challenges in India.
Its strategic initiatives, including collaborations and partnerships with academic institutions, enhance its research capabilities, allowing for the efficient development of RNA therapies. The company’s ability to navigate regulatory landscapes and maintain high manufacturing standards further strengthens its position in the competitive market.
Bharat Biotech is a key player in the India RNA-Based Therapeutics Market, known for its significant contributions to vaccine innovation and development. The company has been at the forefront of addressing public health concerns, particularly during disease outbreaks. Bharat Biotech's strengths include a strong focus on research and development, which has led to the introduction of numerous key products and services in the RNA therapeutic domain. The company has made strategic investments to enhance its manufacturing capabilities and has actively pursued partnerships and collaborations to expand its product offerings.
Recent mergers and acquisitions have further solidified Bharat Biotech's market presence, enabling it to diversify its portfolio and leverage synergies that enhance its position within the RNA therapeutics landscape in India. Through its commitment to innovation and public health, Bharat Biotech plays a pivotal role in shaping the future of RNA-based therapies in the region.
Key Companies in the India RNA-Based Therapeutics Market Include
India RNA-Based Therapeutics Market Industry Developments
The India RNA-Based Therapeutics Market has witnessed notable developments recently, with companies like Wockhardt, Bharat Biotech, and GSK actively participating in advancing RNA technology for various therapeutic applications. In October 2023, Bharat Biotech announced successful preclinical studies for its RNA vaccine targeting respiratory diseases, highlighting a significant investment in Research and Development.
Furthermore, in September 2023, Moderna entered a strategic collaboration with Indian biotech firms to bolster its mRNA vaccine production capabilities in India, reflecting the growing inclination towards local vaccine manufacturing. Noteworthy financial growth has been reported in the RNA therapeutics sector, with Pfizer and Roche increasing their investments to enhance mRNA-based platforms, contributing to market valuation and expansion.
Additionally, in March 2022, Novartis acquired a small biotech company specializing in RNA technology, reinforcing its commitment to this sector in India. The Indian government has been supportive of RNA innovations through funding and policy initiatives, aiming to position the country as a leader in biotechnology and therapeutics. Overall, the RNA-based therapeutics landscape in India is evolving rapidly, driven by strategic collaborations and government backing aimed at fostering innovation and meeting healthcare demands.
India RNA-Based Therapeutics Market Segmentation Insights
RNA-Based Therapeutics Market Technology Outlook
- Antisense Oligonucleotides
RNA-Based Therapeutics Market Application Outlook
RNA-Based Therapeutics Market End Use Outlook
- Contract Research Organizations
RNA-Based Therapeutics Market Delivery Method Outlook
Report Attribute/Metric
|
Details
|
Market Size 2023
|
385.0(USD Million)
|
Market Size 2024
|
524.0(USD Million)
|
Market Size 2035
|
1854.0(USD Million)
|
Compound Annual Growth Rate (CAGR)
|
12.173% (2025 - 2035)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Base Year
|
2024
|
Market Forecast Period
|
2025 - 2035
|
Historical Data
|
2019 - 2024
|
Market Forecast Units
|
USD Million
|
Key Companies Profiled
|
Wockhardt, Bharat Biotech, GSK, Moderna, Amgen, Novartis, Biocon, Pfizer, Roche, Sanofi, AstraZeneca, AbbVie, Johnson & Johnson, Regeneron, Syngene
|
Segments Covered
|
Technology, Application, End Use, Delivery Method
|
Key Market Opportunities
|
Increased government funding initiatives, Rising prevalence of genetic disorders, Growth in cancer therapeutics, Expansion of personalized medicine, Advancements in delivery technologies
|
Key Market Dynamics
|
Growing prevalence of diseases, Increasing investment in biotechnology, Advancements in genetic research, Expanding regulatory frameworks, Rising demand for personalized medicine
|
Countries Covered
|
India
|